Home
LiteratureArticle Details
PMID: 10076592
Published · ppublish
English
Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Infliximab (Remicade) for Crohn's disease.
Abstract
暂无摘要
MeSH Terms
Antibodies, Monoclonal/administration & dosage,adverse effects,economics,therapeutic use
Crohn Disease/therapy
Double-Blind Method
Drug Administration Schedule
Drug Approval
Humans
Immunization, Passive/economics
Infliximab
Injections, Intravenous
Nausea/chemically induced
Tumor Necrosis Factor-alpha/adverse effects,immunology
Chemicals
Antibodies, Monoclonal
Tumor Necrosis Factor-alpha
Infliximab
Article Info
Journal
The Medical letter on drugs and therapeutics
Abbr.
Med Lett Drugs Ther
ISSN
0025-732X
Published
1999-02-26
Pages
19-20
Language
English
Region
United States
NLM ID
2985240R
Subset
IM
Analysis Services
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: product@genelibs.com
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
